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Abstract 
Background: The incidence of outpatient visits for skin and soft tissue infections (SSTIs) has substantially increased 
over the last decade. The emergence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) 
has made the management of S. aureus SSTIs complex and challenging. The objective of this study was to identify risk 
factors contributing to treatment failures associated with community-associated S. aureus skin and soft tissue infec-
tions SSTIs.
Methods: This was a prospective, observational study among 14 primary care clinics within the South Texas Ambula-
tory Research Network. The primary outcome was treatment failure within 90 days of the initial visit. Univariate asso-
ciations between the explanatory variables and treatment failure were examined. A generalized linear mixed-effect 
model was developed to identify independent risk factors associated with treatment failure.
Results: Overall, 21% (22/106) patients with S. aureus SSTIs experienced treatment failure. The occurrence of treat-
ment failure was similar among patients with methicillin-resistant S. aureus and those with methicillin-susceptible S. 
aureus SSTIs (19 vs. 24%; p = 0.70). Independent predictors of treatment failure among cases with S. aureus SSTIs was 
a duration of infection of ≥7 days prior to initial visit [aOR, 6.02 (95% CI 1.74–19.61)] and a lesion diameter size ≥5 cm 
[5.25 (1.58–17.20)].
Conclusions: Predictors for treatment failure included a duration of infection for ≥7 days prior to the initial visit and 
a wound diameter of ≥5 cm. A heightened awareness of these risk factors could help direct targeted interventions in 
high-risk populations.
Keywords: Staphylococcus aureus, Skin and soft tissue infections, Methicillin-resistant Staphylococcus aureus (MRSA), 
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Background
The incidence of outpatient and emergency depart-
ment visits for skin and soft tissue infections (SSTIs) 
has substantially increased with the emergence of 
community-associated methicillin-resistant Staphy-
lococcus aureus (CA-MRSA) [1]. In the U.S., approxi-
mately 80–90% of SSTIs are due to S. aureus [2, 3]. 
Moreover, treatment failure is common after an ini-
tial S. aureus SSTI episode; recurrence rates have 
exceeded 50% in some populations [4]. Treatment fail-
ure may be multifactorial and can be associated with 
host factors, disease management, and pathogen fea-
tures. Two studies set in urgent care and primary care 
clinics found 35% of patients with CA-MRSA SSTIs 
experienced treatment failure and 78% reported SSTI 
recurrence [5, 6]. SSTIs due to CA-MRSA have been 
implicated to have more serious outcomes compared 
to community-associated methicillin susceptible S. 
aureus (CA-MSSA) SSTIs; however, there are limited 
studies evaluating the differences in treatment out-
comes in the primary care setting. Furthermore, while 
there has been a growing body supporting the assess-
ment of early response in treatment failure among hos-
pitalized patients with SSTIs, very little information is 
available for outpatients [7, 8]. Tools to better identify 
those who are at higher risk of experiencing treatment 
failure are needed to better inform treatment decisions 
in the outpatient setting.
We have recently described the prevalence, treatment 
characteristics, and costs associated with the manage-
ment of CA-MRSA SSTIs in South Texas in the primary 
care setting [9, 10]. The primary objective of this study 




We performed this investigation among a well-described 
cohort of patients with SSTIs in the primary care setting. 
Details of this cohort have been described previously 
[9–11]. Briefly, this study was conducted in collaboration 
with fourteen clinics within the South Texas Ambulatory 
Research Network (STARNet), a practice-based research 
network (PBRN) composed of 108 urban, suburban, and 
rural primary care clinics distributed throughout the 
South Texas region, from 2007 to 2014. Patients were 
eligible for study enrollment if they provided informed 
consent, were 18 years of age or older, and presented to 
one of the participating clinics with an SSTI. Healthcare 
providers collected a wound sample and patient informa-
tion (e.g., demographics, infection characteristics, clini-
cal information).
Study design
We conducted a prospective observational cohort study 
to determine predictors of treatment failure. Currently, 
there is no consensus definition of treatment failure. We 
have based our definition based on prior studies using 
a proxy of therapeutic endpoints for SSTIs in the out-
patient setting [9–14]. Treatment failure was defined as 
any of the following events within 90 days of their initial 
visit: (1) need for a new course or change in antibiotic 
therapy for SSTI, (2) additional incision and drainage, (3) 
SSTI at a new site, (4) SSTI at the same site, (5) emer-
gency department visit, or (6) hospital admission. First, 
we compared the rate of treatment failure for patients 
with MRSA infections to those with MSSA infections. 
Next, we identified independent risk factors associated 
with treatment failure by comparing key characteristics 
in those patients who did and did not experience treat-
ment failure.
Microbiologic analyses
Samples were plated onto blood agar plates (TSA with 
5% sheep blood; Fisher Scientific, Lenexa, KS) and incu-
bated at 35–37  °C for 24 h, then sub-cultured to MRSA 
selective agar (MRSASelect chromogenic agar plates; 
Bio-Rad Laboratories, Hercules, CA). Latex agglutination 
tests (StaphAurex®; Thermo Fisher Scientific, Lenexa, 
KS), and phenotypic screening tests (cefoxitin) were used 
for the identification and isolation of MRSA using Vitek 
2 AST-GP75 cards (bioMerieux, Durham, NC). Anti-
microbial minimum inhibitory concentrations (MICs) 
were interpreted according to the Clinical and Labora-
tory Standards Institute document M100-S22 (2012). 
Multidrug resistance (MDR) was defined as resistant to 
>2 antimicrobial classes. For molecular analysis, multilo-
cus sequence types (MLST) were assigned for 98 isolates 
using whole genome sequence data according to desig-
nated MLST (http://www.mlst.net) as described previ-
ously [11].
Data collection and variables
Clinical information included patient gender, race (Black, 
White, Other), ethnicity (Hispanic, Non-Hispanic), past 
medical history (e.g., diabetes, peripheral vascular dis-
ease, chronic non-infectious skin disorder, HIV/AIDS, 
cancer, actively receiving chemotherapy, immunosup-
pression), health care-related work history, skin infection 
history, height, infection characteristics (e.g., location, 
duration, size, deepest tunnel depth, erythema, smell, 
ulceration, drainage, abscess, satellites), incision and 
drainage procedures, and antibiotics prescribed. A BMI 
≥30 kg/m2 was used to indicate obesity status. A 110 kg 
weight cutoff was used to indicate ‘high body weight’. 
Page 3 of 7Lee et al. Ann Clin Microbiol Antimicrob  (2016) 15:58 
This is consistent with previous literature associating 
high body weight with antimicrobial dosing outcomes 
[15–17]. In addition, this cut-off was internally derived 
using a Classification and Regression Tree (CART) analy-
sis which found a significant node at 110  kg that parti-
tioned the data associated with treatment failure.
Statistical analyses
First, a bivariable analysis was conducted comparing 
variables between the ‘treatment failure’ and ‘no treat-
ment failure’ groups. The Breslow-Day test was used 
to identify possible effect modification; any p  ≤  0.05 
was considered an effect modifier. A generalized linear 
mixed-effect model was developed to identify independ-
ent risk factors; clinic site was set as the random effect. 
Covariates included MRSA phenotype, largest diameter 
size of the wound ≥5 cm, and duration of skin infection 
prior to visit of ≥7 days. Adjusted odds ratios (ORs) and 
95% confidence intervals (CIs) were reported. A p ≤ 0.05 
was used to determine statistical significance. SPSS 22.0® 
(IBM Corp, Armonk, NY) was used for all statistical 
comparisons.
Results
Among cases with positive S. aureus SSTIs, 106 cases 
(61%) had 90-days follow-up information. Overall, 22 
(21%) cases experienced treatment failure. Treatment 
failure occurred in 19% (13) of cases with initial MRSA 
SSTIs and 24% (9) with MSSA SSTIs (p = 0.70). In bivari-
able analysis, factors associated with treatment failure 
included Black race, weight ≥110  kg, MDR, duration 
of skin infection prior to visit ≥7  days, lesion diam-
eter ≥5 cm, lesion size ≥25 cm2, and abscess formation 
(Table  1). Multivariable analysis showed no significant 
difference in the likelihood of treatment failure between 
MRSA and MSSA (aOR, 0.42 (0.12–1.42); p  =  0.16). 
Independent predictors of treatment failure among cases 
with S. aureus SSTIs were duration of skin infection 
prior to visit ≥7  days [aOR, 6.02 (95% CI 1.74–19.61)], 
and a lesion diameter size ≥5  cm [aOR, 5.25 (95% CI 
1.58–17.20)].
Infection location, specific treatment strategies, or 
prescribed antimicrobial agents were not significantly 
associated with treatment failure. The proportion of dis-
cordant antimicrobial agents prescribed was higher in the 
treatment failure group than in the no-failure group, but 
did not reach statistical significance (11 vs. 4%, p = 0.20) 
which may be an artifact of the small sample size. MRSA 
isolates had significantly lower susceptibility to ciproflox-
acin (p < 0.01) and erythromycin (p < 0.01). Two isolates 
(1 MRSA and 1 MSSA) were D-test positive.
Molecular analysis (Fig.  1) was conducted on 98 iso-
lates: 56% (65/116) of CA-MRSA and 43% (32/75) of 
CA-MSSA. All MRSA isolates and 68% of MSSA isolates 
were MLST strain type (ST) 8. Other MSSA strain types 
included: ST5, ST12, ST-15, ST-20, ST-45, and ST-59. 
Four isolates had undefined MLST designation. Fur-
thermore, 95% of S. aureus SSTI treatment failures were 
ST-8 compared to 84% of cases with no treatment failure 
(p = 0.32).
Discussion
Over the past 10 years, ambulatory care visits for SSTIs 
have increased exponentially. The worldwide emergence 
of CA-MRSA strains has made the management of S. 
aureus SSTIs extremely complicated and challenging [2, 
3]. A clinical approach to the management of S. aureus 
SSTIs is to identify risk factors to predict those who are 
more likely to experience treatment failure.
Although it has been postulated that CA-MRSA related 
SSTIs may be associated with worse outcomes, SSTIs 
caused by MRSA did not have worse outcomes than 
those caused by MSSA in the South Texas community. 
Miller et  al. found similar 30-day response rates among 
patients with CA-MRSA and CA-MSSA infection (23 
[33%] of 70 vs. 13 [28%] of 47 patients; p = 0.55). In addi-
tion, patients with CA-MSSA infections were more likely 
to be re-hospitalized and to subjectively believe that they 
had not been cured [18]. Moreover, a previous rand-
omized clinical trial of children with suspected S. aureus 
SSTIs found that the incidence of recurrence did not 
differ between children with MRSA vs. MSSA baseline 
infections [14]. Our findings further support the notion 
that the methicillin resistance phenotype is not a reliable 
predictor for clinical outcomes of community associated 
S. aureus infections. Rather, community associated S. 
aureus should be considered a single entity when evaluat-
ing virulence risks.
Identifying predictors for clinical failure can help tar-
get more aggressive treatment, monitoring, and decolo-
nization procedures. This study identified that duration 
of infection 7  days and longer prior to the initial visit 
was the strongest predictor of treatment failure. This 
may be related to the natural course of infection that 
patients were presenting at a time of maximum inten-
sity of inflammation and infection. Moreover, it may be 
that longer duration of an active S. aureus infection with-
out proper treatment may have increased the likelihood 
for household or fomite transmission, both which have 
been shown to be important factors for infection recur-
rence [19–21]. This finding is in contrast to a recent study 
that found longer duration of symptoms was among 
the factors related to early response (at day 3). How-
ever, the investigation evaluated antibiotic response at 
day 3 among hospitalized SSTI patients; therefore, may 
not necessarily be associated with long-term outcomes 
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including post-treatment failure and recurrence that 
were evaluated in the current study [7]. Importantly, 
this finding further supports the proposition that time 
to effective treatment is essential in the management of 
SSTIs, and possibly, that patients presenting with longer 
duration (≥7  days) of infections may require more 
aggressive measures and/or follow-up monitoring.
In addition, a lesion diameter of greater than 5  cm 
was associated with treatment failure. Lesion size has 
been used as a proxy for severity in several syndromes of 
Table 1 Risk factors associated with treatment failure among patients with community-associated S. aureus skin and soft 
tissue infections
Characteristic Overall,  
n = 106
No failure,  
n = 84
Treatment failure,  
n = 22
OR (95% CI) p aOR (95% CI) p
Mean age, years (±SD) 41 (±14) 40 (±13) 45 (±13) 0.15
Gender
 Male 53 (50%) 44 (52%) 9 (41%) 0.63 (0.24–1.63) 0.34
Race/ethnicity
 Black 8 (8%) 4 (5%) 4 (18%) 4.44 (1.02–19.47) 0.03
 Hispanic 78 (74%) 64 (76%) 14 (64%) 0.547 (0.20–1.49) 0.23
 Diabetes 28 (26%) 21 (25%) 7 (32%) 1.40 (0.50–3.89) 0.52
 Obese (BMI ≥ 30)b 50 (54%) 38 (50%) 12 (71%) 2.40 (0.77–7.48) 0.12
 Weight ≥110 kg 19 (20%) 12 (15%) 7 (37%) 3.21 (1.05–9.80) 0.04
 Chronic non-infectious skin 
disorder
1 (1%) 1 (1%) 0 0.99 (0.97–1.01) 1.00
 Immunosuppressed at time 
of visit
2 (2%) 2 (2%) 0 0.98 (0.94–1.01) 1.00
 Provides healthcare to 
others
2 (2%) 1 (1%) 0 0.99 (0.97–1.01) 1.00
 MRSA phenotype 68 (65%) 55 (66%) 13 (59%) 0.87 (0.49–1.56) 0.65 0.42 (0.12–1.42) 0.16
 MDR 29 (27%) 10 (12%) 19 (86%) 2.85 (1.07–7.62) 0.03
 Prior SSTI 35 (33%) 27 (32%) 8 (36%) 1.21 (0.45–3.20) 0.71
 Prior antibiotic history 16 (15%) 11 (13%) 5 (23%) 1.95 (0.60–6.36) 0.32
 Duration of infection prior 
to visit ≥7 days
48 (48%) 32 (40%) 16 (76%) 4.80 (1.59–14.41) <0.01 6.02 (1.74–20.87) <0.01
 Severity
 Largest diameter ≥5 cm 49 (48%) 34 (42%) 15 (71%) 3.53 (1.24–10.02) 0.01 5.25 (1.58–17.42) <0.01
 Lesion area ≥25 cm2 37 (35%) 24 (29%) 13 (59%) 3.55 (1.34–9.39) 0.01
Infection characteristics
 Erythema 78 (74%) 61 (74%) 17 (77%) 1.23 (0.40–3.72) 0.72
 Drainage 56 (53%) 45 (54%) 11 (50%) 0.84 (0.33–2.16) 0.72
 Ulceration 30 (29%) 22 (27%) 8 (36%) 1.58 (0.59–4.29) 0.43
 Abscess 76 (72%) 56 (67%) 20 (91%) 4.82 (1.05–22.14) 0.03
Location
 Lower extremity 35 (33%) 26 (31%) 9 (41%) 1.54 (0.59–4.06) 0.38
 Head/neck/face 11 (10%) 10 (12%) 1 (5%) 0.35 (0.40–2.91) 0.45*
 Trunk 24 (23%) 17 (20%) 7 (32%) 1.84 (0.65–5.22) 0.26*
 Axilla 13 (12%) 11 (13%) 2 (9%) 0.66 (0.14–3.24) 0.61*
 Upper extremity 6 (6%) 5 (6%) 1 (5%) 0.75 (0.08–6.79) 1.00*
 Groin/buttock 17 (16%) 14 (17%) 3 (14%) 0.79 (0.21–3.03) 1.00*
Treatment
 I&D only 4 (4%) 3 (4%) 1 (5%) 1.01 (0.91–1.12) 1.00
 I&D + antibiotics 57 (59%) 43 (51%) 14 (64%) 1.30 (0.68–2.51) 0.41




81 (76%) 65 (77%) 16 (73%) 0.78 (0.27–2.27) 0.65
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skin infections, including necrotizing fasciitis and surgi-
cal site infections [22]. The 5  cm threshold used in this 
study was based on data from an observational study, in 
which abscesses larger than 5  cm were associated with 
treatment failure [23]. This investigation found a signifi-
cant predictor of hospitalization on the first follow-up 
was having an infected area >5  cm in diameter at the 
initial evaluation (33% of patients with diameter >5  cm 
were later hospitalized vs. none with diameter ≤5  cm; 
p  =  0.004). Other studies have also identified lesion 
size as an important indicator for severity and sug-
gest treatment stratification approaches [24–26]. In the 
most recent guidelines for acute bacterial skin and skin 
structure infection (ABSSSI) clinical trials, the FDA rec-
ommends an evaluation of lesion size as a more quanti-
tative assessment of infection severity and the change in 
lesion size at 48 to 72 h as the new primary endpoint [27]. 
Our findings provide further support to assess initial 
lesion sizes to predict infection severity and treatment 
outcomes.
Specific treatment strategies or type of prescribed anti-
microbial agents were not found to be independent fac-
tors associated with treatment failure. It should be noted 
that because of the limited sample size, this study was 
not designed to perform direct comparisons of treatment 
approaches and antibiotic therapies. Larger investiga-
tions are needed to compare the role of treatment strate-
gies and antibiotic regimens.
In our molecular analyses, ST-8 was the predominant 
strain type and was more likely to be found in patients 
whose treatment failed. However, this 11% absolute dif-
ference did not reach statistical significance due to the 
size of our cohort. This might suggest that the patho-
genicity of community associated S. aureus may be based 
Table 1 continued
Characteristic Overall,  
n = 106
No failure,  
n = 84
Treatment failure,  
n = 22
OR (95% CI) p aOR (95% CI) p
 Doxycycline 12 (11%) 9 (11%) 3 (14%) 1.32 (0.32–5.34) 0.71
 Clindamycin 7 (7%) 5 (6%) 2 (9%) 1.58 (0.26–8.75) 0.63
 Cephalexin 9 (9%) 7 (8%) 2 (9%) 1.10 (0.21–5.71) 1.00
Discordant therapy 5 (5%) 3 (4%) 2 (11%) 2.82 (0.44–18.24) 0.26
Note there were no cases of patients with the peripheral vascular disease, human immunodeficiency virus, cancer, and receipt of chemotherapy
MRSA methicillin resistant S. aureus, MSSA methicillin susceptible S. aureus, SD standard deviation, OR odds ratio, CI confidence interval, aOR adjusted odds ratio, SSTI 
skin and soft tissue infection, BMI body mass index, I&D incision and drainage
* Fishers exact test was used
Fig. 1 Multilocus sequence typing of Staphylococcus aureus isolates associated with treatment failure or no treatment failure
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on the genetic background or lineage rather than the 
methicillin susceptibility phenotype. A more thorough 
investigation on the genomic characteristics of these 
strains is currently underway.
There are limitations to this study. First, we did not 
account for social and behavioral risk factors that may 
be associated with S. aureus SSTIs and/or clinical out-
comes. Second, we used laboratory diagnosis to iden-
tify S. aureus cases. Patients presenting with SSTIs with 
no culture or were culture-negative may have different 
characteristics. The small sample size limited the ability 
to identify risks associated with lower exposures. Com-
pliance of antimicrobials prescribed was not assessed. 
Finally, there may be limited generalizability to other 
regions outside of South Texas. To our knowledge, this is 
the first prospective study evaluating the clinical and epi-
demiological factors of S. aureus SSTI treatment failure 
in the primary care setting, adding important findings to 
the sparse literature in this growing population.
Conclusions
The rates of treatment failure were similar among 
patients with CA-MRSA SSTIs to those with CA-MSSA 
SSTIs. Independent predictors for treatment failure 
included a duration of infection for greater than 7  days 
prior to the initial visit and a wound diameter of ≥5 cm. 
A heightened awareness of these risk factors could help 
direct clinical management and public health interven-
tions in high-risk populations. Future large prospective 
investigations are required to validate these findings and 
to assess optimal treatment approaches.
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